AI Pharmaceutical Platforms.
Defensible decisions, certified narratives.
The EYQA Framework provides a structured pathway to validate platform claims — ensuring every strategic choice holds under institutional scrutiny.
Traditional drug discovery is notoriously slow, expensive, and failure-prone. On average, it takes over 10 years and $2 billion to bring a single drug to market, with more than 90% of candidates failing during clinical trials.
✦ EYQA Narrative Defensibility Lens: AI platform evaluations are high-stakes narratives — investors, boards, and partners will challenge your assumptions. The EYQA six-dimension framework (Evidence, Logic, Perspective, Risk Awareness, Contextual Fit, Actionability) ensures your platform selection narrative is built to withstand independent scrutiny, not just internal consensus.
AI is no longer an optional efficiency tool—it's a survival strategy. By leveraging massive biomedical datasets, predictive modeling, and generative algorithms, AI can cut discovery timelines by years, reduce costs, and increase probability of success.
- Target Identification (Smarter) — AI uncovers novel drug targets invisible to conventional methods.
- Generative Chemistry (Faster) — Algorithms propose new molecular structures with optimal binding properties.
- Predictive Modeling (Safer) — In silico simulations forecast toxicity, efficacy, and pharmacokinetics.
- Drug Repurposing (Faster + Smarter) — AI finds new therapeutic uses for existing drugs.
Exscientia has pioneered AI-driven drug design with its automated platform that combines multiple data sources to optimize drug candidates.
Atomwise uses convolutional neural networks to analyze molecular structures and predict binding affinity at unprecedented scale.
Insilico's generative adversarial networks (GANs) create novel molecular structures with desired properties, accelerating discovery.
Recursion combines automated cell biology with AI to decode human biology and discover new treatments.
Deep Genomics specializes in AI-powered RNA therapeutics, targeting previously undruggable genetic mutations.
Schrödinger's platform combines physics-based modeling with machine learning for highly accurate molecular simulations.
NVIDIA's platform leverages GPU computing power to accelerate molecular simulations and AI model training.
BenevolentAI builds vast knowledge graphs that connect biomedical data to uncover novel drug targets and repurposing opportunities.
PharmAI's DiscoveryEngine specializes in structural binding site analysis to identify potential off-target effects early in drug development, covering up to 95% of the human proteome.
Every platform decision tells a story. Use the six EYQA dimensions to stress-test your strategic narrative:
Focus: Generative chemistry for rapid drug design
Best for: Startups needing fast preclinical candidates
Case: Designed novel anti-fibrosis drug in 18 months
Focus: Automated precision drug design
Best for: All company sizes needing end-to-end automation
Case: First AI-designed molecule in clinical trials (12 months)
Focus: Massive-scale virtual screening
Best for: Startups needing affordable screening
Case: Screened 10B molecules for Ebola in a week
Focus: Off-target effect screening
Best for: Safety-conscious organizations
Case: Screened 95% of human proteome in 4 weeks
Focus: Knowledge graphs for target discovery
Best for: Companies needing biomedical insights
Case: Repurposed baricitinib for COVID-19
Focus: Physics-based molecular modeling
Best for: Enterprise-scale precision modeling
Case: Accelerated oncology programs for Bristol Myers Squibb
Focus: GPU-accelerated simulations
Best for: Large-scale computational needs
Case: Reduced GSK's workloads from weeks to hours
Focus: Phenomics at scale
Best for: Complex disease research
Case: Mapped 3T phenotypic points for CCM
Focus: RNA-focused discovery
Best for: Genetic mutation targeting
Case: RNA therapy for Wilson's disease in 18mo
- Hurdles: Data quality issues, lack of clear AI regulatory pathways, and model interpretability challenges.
- Opportunities: Autonomous labs integrating robotics with AI, quantum computing for molecular simulation, and democratized discovery enabling global competition.
The race is no longer about who adopts AI, but who adopts it fastest. Platforms like Exscientia, Insilico Medicine, and BenevolentAI already show that accelerated timelines, safety-first screening, and intelligent design are possible today.
Call-to-Action: Pharma companies must act now—AI adoption is a survival strategy, not a luxury. The future standard is clear: faster, safer, smarter drug discovery for a world that can't afford to wait.
Authored by Pankaj and Rashmi Mendiratta, Founder EYQA®
Last updated on August 12, 2025
EYQA Platform Review Methodology: The EYQA Platform Review Methodology uses a data-driven, FAB (Features, Advantages, Benefits) approach to help CxO leaders make informed decisions about business platforms. We assess key Features like usability and integrations, revealing Advantages such as boosting experience, yield, quality, and agility and smoother workflows. These lead to the ultimate Benefits: solutions tailored to organizations' specific needs, driving transformative change—across strategy, design, engineering, and operations.
With extensive experience evaluating platforms, our refined process simplifies business platform selection. It has proven invaluable to organizations seeking clear, actionable insights.